메뉴 바로가기 본문 바로가기

ST2

What is it:

sST2 is a member of the interleukin-1 (IL-1) receptor family and it can be found in a transmembrane form (ST2 ligand or ST2L) and a soluble, circulating form (sST2). IL-33 when bound with ST2L protects the myocardium against hypertrophy and cardiac fibrosis. However Soluble ST2 acts as a decoy receptor for IL-33 and prevents the IL-33/ST2L interaction.


Value of sST2 analysis

Higher concentration of soluble ST2 is associated with increased myocardial fibrosis, adverse cardiac remodeling, and
worse cardiovascular outcomes. 1, 2
Studies shows that the changes in sST2 level during follow up patients admitted with acute HF represent a strong, independent predictor of the composite endpoint of all-cause mortality or readmission for HF over at least 1 year follow-up. 1, 3, 4


sST2 and other biomarkers

Biomarkers have become an integral part of medicine, aiding in the diagnosis and treatment of numerous conditions. Natriuretic peptides, troponin, ST2 and procalcitonin, all provide significant information for the doctor to know which is the best treatment for a patient presenting at the hospital with chest pain, shortness of breath, sign of infections, etcetera.
Biomarkers also can help decide on appropriateness of discharge and follow up frequency.
All these parameters work together to provide the most vivid picture for the clinician to consider and adapt the therapy to the single patient.5, 6

References
  • 1. van Vark LC, Lesman-Leegte I, Baart SJ, et al., Prognostic value of serial ST2 measurements in patients with acute heart failure, Journal of the American College of Cardiology 2017;70:2378–88.;
  • 2. Antoni Bayés-Genís, Julio Núñez, Josep Lupón, Soluble ST2 for Prognosis and Monitoring in Heart Failure, journal of the American College of Cardiology, VOL. 70, NO. 19, 2017
  • 3. Gaggin HK, Szymonifka J, Bhardwaj A, et al., Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure, Journal of the American College of Cardiology HF 2014;2:65–72.
  • 4. Weir RA, Miller AM, Murphy GE, et al., Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction, Journal of the American College of Cardiology 2010;55: 243–50.
  • 5. Breidthardt T, Balmelli C, Twerenbold R, et al., Heart failure therapy - induced early ST2 changes may offer long-term therapy guidance., Journal of Cardiac Failure 2013;19:821–8.
  • 6. Nicholas Wettersten, Alan S. Maisel, Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine, The American Journal of Medicine, 2016 Jun;129(6):560-7. doi: 10.1016/j.amjmed.2016.01.013. Epub 2016 Feb 1


ST2 product is a collaboration between Boditech Med Inc and Critical Diagnostics. :http://www.criticaldiagnostics.com/

ichroma™

Compatible Device ichroma™ II
Detection Range 3.1~200 ng/mL
Sample Type Whole Blood, Serum,
Plasma, Capillary Blood
CV <10%
Comparability 0.9954
Reaction Time 12 minutes
Available Instruments

AFIAS

Compatible Device AFIAS-1/6
Detection Range 3.1~200 ng/mL
Sample Type Whole Blood, Serum,
Plasma, Capillary Blood
CV <10%
Comparability 0.9954
Reaction Time 12 minutes
Available Instruments

Product News